Counterfeit forms of weight loss and diabetes drugs are endangering consumers, and Oklahoma General Attorney Gentner Drummond wants to take action against what he calls "bad actors" in the ...

Nestle SA is launching GLP-1-friendly beverages under its Boost brand that contain a proprietary whey protein microgel technology, according to the company. Nestle said the innovation allows for more ...

While medications like Ozempic and Wegovy are delivering positive weight loss outcomes, many consumers only use them for a relatively short period, giving better-for-you brands and retailers an ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

Pfizer abandoned the development of danuglipron and plans to focus its efforts on GIPR candidates and other earlier obesity programs.

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Morgan Stanley analyst Terence Flynn notes that Pfizer (PFE) announced that after a review of the totality of the data for its pipeline oral ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...